These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29431006)

  • 1. Cell Density-Dependent Cytological Stage Profile and Its Application for a Screen of Cytostatic Agents Active Toward Leukemic Stem Cells.
    Lica JJ; Grabe GJ; Heldt M; Misiak M; Bloch P; Serocki M; Switalska M; Wietrzyk J; Baginski M; Hellmann A; Borowski E; Skladanowski A
    Stem Cells Dev; 2018 Apr; 27(7):488-513. PubMed ID: 29431006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cantharidins on leukemic stem cells.
    Dorn DC; Kou CA; Png KJ; Moore MA
    Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential induction of apoptosis for primary human leukemic stem cells.
    Guzman ML; Swiderski CF; Howard DS; Grimes BA; Rossi RM; Szilvassy SJ; Jordan CT
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16220-5. PubMed ID: 12451177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
    Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
    Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
    Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
    Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
    Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.
    Singer E; Judkins J; Salomonis N; Matlaf L; Soteropoulos P; McAllister S; Soroceanu L
    Cell Death Dis; 2015 Jan; 6(1):e1601. PubMed ID: 25590811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics.
    Lee MH; Lapidus RG; Ferraris D; Emadi A
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31466259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
    Zada AA; Singh SM; Reddy VA; Elsässer A; Meisel A; Haferlach T; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Apr; 22(15):2296-308. PubMed ID: 12700665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells.
    Ji Q; Ding YH; Sun Y; Zhang Y; Gao HE; Song HN; Yang M; Liu XL; Zhang ZX; Li YH; Gao YD
    Oncotarget; 2016 Oct; 7(40):65012-65023. PubMed ID: 27542251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.